Literature DB >> 22426792

Serum levels and genotype distribution of α1-antitrypsin in the general population.

Ilaria Ferrarotti1, Gian Andri Thun, Michele Zorzetto, Stefania Ottaviani, Medea Imboden, Christian Schindler, Arnold von Eckardstein, Lucia Rohrer, Thierry Rochat, Erich W Russi, Nicole M Probst-Hensch, Maurizio Luisetti.   

Abstract

RATIONALE: α1-Antitrypsin (AAT) deficiency is one of the commonest rare respiratory disorders worldwide. Diagnosis, assessment of risk for developing chronic obstructive pulmonary disease (COPD), and management of replacement therapy require the availability of precise and updated ranges for protein serum levels.
OBJECTIVE: This paper aims to provide ranges of serum AAT according to the main genotype classes in the general population.
METHODS: The authors correlated mean AAT serum levels with the main SERPINA1 variants (M1Ala/M1Val (rs6647), M3 (rs1303), M2/M4 (rs709932), S (rs17580) and Z (rs28929474)) in 6057 individuals enrolled in the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) cohort.
RESULTS: The following ranges (5th-95th percentile) of AAT were found in the serum (g/litre): 1.050-1.640 for PI*MM, 0.880-1.369 for PI*MS, 0.730-1.060 for PI*SS, 0.660-0.997 for PI*MZ and 0.490-0.660 for PI*SZ. There was very little overlap in AAT serum levels between genotype classes generally not believed to confer an enhanced health risk (MM and MS) and those associated with an intermediate AAT deficiency and a potentially mildly enhanced health risk (SS, MZ).
CONCLUSION: This work resulted in three important findings: technically updated and narrower serum ranges for AAT according to PI genotype; a suggestion for a population-based 'protective threshold' of AAT serum level, used in decision-making for replacement therapy; and more precise ranges framing the intermediate AAT deficiency area, a potential target for future primary prevention.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22426792     DOI: 10.1136/thoraxjnl-2011-201321

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  47 in total

Review 1.  Mechanistic evidence in support of alpha1-antitrypsin as a therapeutic approach for type 1 diabetes.

Authors:  Gabriella Fleixo-Lima; Hilla Ventura; Michal Medini; Liliana Bar; Pnina Strauss; Eli C Lewis
Journal:  J Diabetes Sci Technol       Date:  2014-08-25

2.  A novel alpha1-antitrypsin null variant (PiQ0Milano ).

Authors:  Raffaela Rametta; Gabriella Nebbia; Paola Dongiovanni; Marcello Farallo; Silvia Fargion; Luca Valenti
Journal:  World J Hepatol       Date:  2013-08-27

3.  Common coding variant in SERPINA1 increases the risk for large artery stroke.

Authors:  Rainer Malik; Therese Dau; Maria Gonik; Anirudh Sivakumar; Daniel J Deredge; Evgeniia V Edeleva; Jessica Götzfried; Sander W van der Laan; Gerard Pasterkamp; Nathalie Beaufort; Susana Seixas; Steve Bevan; Lisa F Lincz; Elizabeth G Holliday; Annette I Burgess; Kristiina Rannikmäe; Jens Minnerup; Jennifer Kriebel; Melanie Waldenberger; Martina Müller-Nurasyid; Peter Lichtner; Danish Saleheen; Peter M Rothwell; Christopher Levi; John Attia; Cathie L M Sudlow; Dieter Braun; Hugh S Markus; Patrick L Wintrode; Klaus Berger; Dieter E Jenne; Martin Dichgans
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-06       Impact factor: 11.205

4.  Characteristics of Chronic Obstructive Pulmonary Disease (COPD) Patients Reporting Alpha-1 Antitrypsin Deficiency in the WebMD Lung Health Check Database.

Authors:  Tyler McGrady; David M Mannino; Elisha Malanga; Byron M Thomashow; John Walsh; Robert A Sandhaus; James K Stoller
Journal:  Chronic Obstr Pulm Dis       Date:  2015-04-15

5.  Clarifying the Risk of Lung Disease in SZ Alpha-1 Antitrypsin Deficiency.

Authors:  Alessandro N Franciosi; Brian D Hobbs; Oliver J McElvaney; Kevin Molloy; Craig Hersh; Louise Clarke; Cedric Gunaratnam; Edwin K Silverman; Tomás P Carroll; Noel G McElvaney
Journal:  Am J Respir Crit Care Med       Date:  2020-07-01       Impact factor: 21.405

Review 6.  Why is Disease Penetration so Variable in Alpha-1 Antitrypsin Deficiency? The Contribution of Environmental Factors.

Authors:  Madhu Rangaraju; Alice M Turner
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

Review 7.  Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis.

Authors:  Timm Greulich; Claus F Vogelmeier
Journal:  Ther Adv Respir Dis       Date:  2015-09-04       Impact factor: 4.031

8.  Pleiotropic associations of heterozygosity for the SERPINA1 Z allele in the UK Biobank.

Authors:  Katherine A Fawcett; Kijoung Song; Guoqing Qian; Aliki-Eleni Farmaki; Richard Packer; Catherine John; Nick Shrine; Raquel Granell; Sue Ring; Nicholas J Timpson; Laura M Yerges-Armstrong; Richard Eastell; Louise V Wain; Robert A Scott; Martin D Tobin; Ian P Hall
Journal:  ERJ Open Res       Date:  2021-05-10

9.  A reference panel of 64,976 haplotypes for genotype imputation.

Authors:  Shane McCarthy; Sayantan Das; Warren Kretzschmar; Olivier Delaneau; Andrew R Wood; Alexander Teumer; Hyun Min Kang; Christian Fuchsberger; Petr Danecek; Kevin Sharp; Yang Luo; Carlo Sidore; Alan Kwong; Nicholas Timpson; Seppo Koskinen; Scott Vrieze; Laura J Scott; He Zhang; Anubha Mahajan; Jan Veldink; Ulrike Peters; Carlos Pato; Cornelia M van Duijn; Christopher E Gillies; Ilaria Gandin; Massimo Mezzavilla; Arthur Gilly; Massimiliano Cocca; Michela Traglia; Andrea Angius; Jeffrey C Barrett; Dorrett Boomsma; Kari Branham; Gerome Breen; Chad M Brummett; Fabio Busonero; Harry Campbell; Andrew Chan; Sai Chen; Emily Chew; Francis S Collins; Laura J Corbin; George Davey Smith; George Dedoussis; Marcus Dorr; Aliki-Eleni Farmaki; Luigi Ferrucci; Lukas Forer; Ross M Fraser; Stacey Gabriel; Shawn Levy; Leif Groop; Tabitha Harrison; Andrew Hattersley; Oddgeir L Holmen; Kristian Hveem; Matthias Kretzler; James C Lee; Matt McGue; Thomas Meitinger; David Melzer; Josine L Min; Karen L Mohlke; John B Vincent; Matthias Nauck; Deborah Nickerson; Aarno Palotie; Michele Pato; Nicola Pirastu; Melvin McInnis; J Brent Richards; Cinzia Sala; Veikko Salomaa; David Schlessinger; Sebastian Schoenherr; P Eline Slagboom; Kerrin Small; Timothy Spector; Dwight Stambolian; Marcus Tuke; Jaakko Tuomilehto; Leonard H Van den Berg; Wouter Van Rheenen; Uwe Volker; Cisca Wijmenga; Daniela Toniolo; Eleftheria Zeggini; Paolo Gasparini; Matthew G Sampson; James F Wilson; Timothy Frayling; Paul I W de Bakker; Morris A Swertz; Steven McCarroll; Charles Kooperberg; Annelot Dekker; David Altshuler; Cristen Willer; William Iacono; Samuli Ripatti; Nicole Soranzo; Klaudia Walter; Anand Swaroop; Francesco Cucca; Carl A Anderson; Richard M Myers; Michael Boehnke; Mark I McCarthy; Richard Durbin
Journal:  Nat Genet       Date:  2016-08-22       Impact factor: 38.330

10.  The Clinical Utility of Determining the Allelic Background of Mutations Causing Alpha-1 Antitrypsin Deficiency: The Case with the Null Variant Q0(Mattawa)/Q0(Ourém).

Authors:  Judith Bellemare; Nathalie Gaudreault; Kim Valette; Irene Belmonte; Alexa Nuñez; Marc Miravitlles; François Maltais; Yohan Bossé
Journal:  Chronic Obstr Pulm Dis       Date:  2021-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.